Two trials could change clinical practice for certain subtypes of renal cell carcinoma (RCC). In one, the combination of lenvatinib and pembrolizumab was superior to sunitinib and to lenvatinib plus everolimus in clear-cell RCC. In the other, cabozantinib was more effective than sunitinib in papillary RCC.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.